Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly owned subsidiary KGK Science Inc has been awarded an institution-wide cannabis research license for its state-of-the-art facility by Health Canada, allowing the company to possess cannabis for research and development.
In a statement, Wellbeing said that the research license greatly reduces the timelines required for conducting cannabis research and facilitates the ability for KGK to apply for cannabis import permits without first having to obtain project-specific research licenses.
“The research license allows KGK to conduct clinical trials investigating cannabis for both non-therapeutic and therapeutic purposes, as well as on-site sensory assessments of cannabis products, without having to obtain project-specific cannabis research licenses, ultimately accelerating our research programs and reducing the time to market,” commented Najla Guthrie, CEO of Wellbeing and KGK.
READ: Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response
A subsidiary of Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF), KGK Science is a leading North American contract research organization based in London, Ontario, that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging healthcare products.
Wellbeing Digital Sciences is an evidence-based mental healthcare company focused on developing and implementing innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie